Investors should monitor upcoming BLA submission in Q3 2026 and Phase 3 topline data in Q1 2027 as key catalysts. The gene-agnostic mechanism could position OCU400 as a first-in-class therapy with broad market potential.
Price Chart
Executive Summary
Ocugen announced completion of patient enrollment in the Phase 3 liMeliGhT trial for its gene therapy OCU400 in retinitis pigmentosa (RP), with topline data expected in Q1 2027. The company also reported positive 3-year Phase 1/2 data showing durable vision improvement and a favorable safety profile, reinforcing the potential for a gene-agnostic treatment. BLA filing is on track for Q3 2026.
Key Facts
- Enrollment completed in OCU400 Phase 3 liMeliGhT trial with 140 patients randomized 2:1 across RHO and gene-agnostic RP mutations.
- Topline Phase 3 data expected in Q1 2027, supporting potential approval in 2027.
- Positive 3-year Phase 1/2 data show 88% of treated eyes maintained or improved vision, with ~2-line LLVA gain sustained across mutations.
- No new treatment-related serious adverse events reported; safety profile remains favorable.
- Rolling BLA submission planned for Q3 2026; EMA accepts U.S. trial data for future MAA submission.
Financial Impact
Potential blockbuster revenue if approved, given no current gene-agnostic therapy for RP and ~98% of RP patients lack treatment options.
Risk Factors
- Phase 3 results may not replicate Phase 1/2 durability or efficacy.
- Regulatory delays or rejection despite EMA acceptability opinion.
- High development risk typical of gene therapies in late-stage trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247241 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 4w ago | Press Release | $1.33 $1.05 | ▼ −21.05% | ▼ −22.23% | $1.02 (−23.31%) |
Jul 13, 2026 11w ago | 8-K | $1.41 $1.31 | ▼ −7.09% | ▼ −10.28% | $1.02 (−27.66%) |
Jun 11, 2026 16w ago | 8-K | $1.21 $1.47 | ▲ +21.49% | ▲ +19.71% | $1.02 (−15.70%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.22 $1.47 | ▲ +20.49% | ▲ +18.60% | $1.02 (−16.39%) |
May 5, 2026 21w ago | 8-K | $1.49 $1.34 | ▼ −10.07% | ▼ −15.02% | $1.02 (−31.54%) |
May 5, 2026 21w ago | Press Release | $1.49 $1.34 | ▼ −10.07% | ▼ −15.02% | $1.02 (−31.54%) |
May 5, 2026 21w ago | Press Release | $1.49 $1.34 | ▲ +10.07% | ▲ +15.02% | $1.02 (+31.54%) |
May 4, 2026 21w ago | 8-K | $1.49 $1.34 | ▼ −10.07% | ▼ −15.02% | $1.02 (−31.54%) |
Apr 29, 2026 22w ago | Press Release | $1.68 $1.38 | ▼ −17.86% | ▼ −23.32% | $1.02 (−39.29%) |
Mar 24, 2026 27w ago | Press Release | $1.92 $1.68 | ▼ −12.50% | ▼ −21.40% | $1.02 (−46.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access